Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS 46 Receivables Turnover is 7.25 as of Dec. 2025. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 841 Biotechnology companies, BLS Pharmaceuticals ranks better than 79.31% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BLS Pharmaceuticals's Revenue for the
six
months ended in Dec. 2025 was A$31.31 Mil. BLS Pharmaceuticals's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$4.32 Mil.
Hence, BLS Pharmaceuticals's Receivables Turnover for the
six
months ended in Dec. 2025 was 7.25.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BLS Pharmaceuticals Receivables Turnover Related Terms
BLS Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BLS vs KHC, GIS: Receivables Turnover Comparison
For the Biotechnology subindustry, BLS Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (ASX:BLS) has a Receivables Turnover of 7.25 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BLS Pharmaceuticals and its competitors. According to the industry distribution chart, BLS Pharmaceuticals ranks #174 out of 841 companies in the Biotechnology industry, placing it in the top 20.7%.
Is BLS Pharmaceuticals' Receivables Turnover too high?
BLS Pharmaceuticals' current Receivables Turnover is 7.25. The Biotechnology industry median Receivables Turnover is 5.29. BLS Pharmaceuticals' value of 7.25 is 37.1% above this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #174 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Receivables Turnover compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #174 out of 841 companies for Receivables Turnover. This places BLS Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. BLS Pharmaceuticals' value of 7.25 is 37.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current Receivables Turnover of 7.25 is 37.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Receivables Turnover is 7.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current Receivables Turnover is 7.25 and 37.1% above the Biotechnology industry median of 5.29. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Receivables Turnover is 7.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
Receivables Turnover: 7.25
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
Industry Position: 37.1% above the Biotechnology median (#174 of 841)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
